Looks for genes that affect sickle cell disease and thalassemia
Studies genetic differences in people with sickle cell disease or thalassemia.
Plain-language title generated from the registry record
Registry title: Study of the Role of Genetic Modifiers in Hemoglobinopathies
Key facts
- Where
- Copenhagen, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with an inherited blood disorder of haemoglobin: sickle cell disease, beta-thalassemia or alpha-thalassemia. It studies genes that change how these diseases behave.
- Age
- 2 years or older at the time the study data are collected.
- Sex
- All sexes can join. There are no limits by gender or ethnicity.
- Disease stage
- A clinical diagnosis of an inherited hemoglobinopathy: sickle cell disease, β-thalassemia or α-thalassemia. All genotypes are considered.
- Earlier treatment
- People who were treated with stem cell transplantation or genetic therapy cannot join.
Main reasons for not taking part
- Treated with stem cell transplantation or genetic therapy
- Younger than 2 years at the time the study data are collected
- Patient, or legal representative for a minor, unwilling or unable to give consent
Read by machine on 9 November 2026.
Where in Denmark
- RigshospitaletCopenhagen, DenmarkContact: Andreas Birkedal Glenthøj, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cyprus Institute of Neurology and Genetics
- Trial code
- NCT05799118
- Record updated
- 20 March 2024
- Original description
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).Read full original descriptionShow less
Study of the Role of Genetic Modifiers in Hemoglobinopathies
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Inclusion: Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered; Age ≥ 2 years old at the time of the collection of the phenotypic data; There will be no limits on study participants in terms of gender, ethnicity, morbidities.
Exclusion: Patients treated with stem cell transplantation or genetic therapy; Age < 2 years old at the time of the collection of the phenotypic data; Patient or legal representative for minors unwilling or unable to give consent.